Anteris Strengthens Clinical Progress and Board Leadership in Q1 2026
Anteris Technologies Global Corp. (ASX: AVR) reported solid progress during the first quarter of 2026 as it continued advancing the global PARADIGM Trial for its DurAVR® Transcatheter Heart Valve system. The company completed capital raises worth US$320 million to support clinical execution, manufacturing scale-up, and commercialization initiatives. Patient enrolment progressed across Europe, while U.S. enrolment commenced following Medicare coverage support under the CMS National Coverage Determination framework. Anteris also presented encouraging clinical data from its EMBARK Study and Early Feasibility Study at major cardiovascular conferences, reinforcing engagement with the medical community.
Financially, the company recorded net operating cash outflows of US$28.7 million, largely driven by research, manufacturing expansion, regulatory activities, and clinical trial operations. R&D expenses rose to US$17.5 million due to increased manufacturing capability, quality validation processes, and expansion of the clinical team. Additionally, Anteris strengthened its governance framework by appointing Susan Knight and Stephen Denaro to its Board of Directors, adding extensive financial, operational, and industry expertise to support long-term growth plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Anteris Strengthens Clinical Progress and Board Leadership in Q1 2026
Anteris Technologies Global Corp. (ASX: AVR) reported solid progress during the first quarter of 2026 as it continued advancing the global PARADIGM Trial for its DurAVR® Transcatheter Heart Valve system. The company completed capital raises worth US$320 million to support clinical execution, manufacturing scale-up, and commercialization initiatives. Patient enrolment progressed across Europe, while U.S. enrolment commenced following Medicare coverage support under the CMS National Coverage Determination framework. Anteris also presented encouraging clinical data from its EMBARK Study and Early Feasibility Study at major cardiovascular conferences, reinforcing engagement with the medical community.
Financially, the company recorded net operating cash outflows of US$28.7 million, largely driven by research, manufacturing expansion, regulatory activities, and clinical trial operations. R&D expenses rose to US$17.5 million due to increased manufacturing capability, quality validation processes, and expansion of the clinical team. Additionally, Anteris strengthened its governance framework by appointing Susan Knight and Stephen Denaro to its Board of Directors, adding extensive financial, operational, and industry expertise to support long-term growth plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au